Business Context and Reporting Period
Company: Nektar Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Nektar is a clinical-stage biopharmaceutical company developing drug candidates using PEGylation and advanced polymer conjugate technology platforms. The company operates in a single business segment focusing on oncology, pain, anti-infectives, and immunology. Results for the current period are not fully comparable to the prior year due to the sale of pulmonary assets to Novartis on December 31, 2008.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Total Revenue | $10,223 | $32,922 | - |
| Net Loss | $(30,967) | $(94,843) | - |
| Loss Per Share (Basic/Diluted) | $(0.33) | $(1.02) | - |
| Cash & Cash Equivalents | - | - | $32,777 |
| Short-term Investments | - | - | $242,901 |
| Total Liquidity (Cash + Investments) | - | - | $275,678 |
| Convertible Subordinated Notes | - | - | $214,955 |
| Capital Lease Obligations | - | - | $19,228 |
| Product Gross Margin | 24% | 14% | - |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 52% for the three months and 47% for the nine months ended September 30, 2009, compared to the same periods in 2008. This is primarily due to the termination of the Tobramycin Inhalation Powder (TIP) collaboration with Novartis and the assignment of the Cipro Inhale agreement to Novartis following the asset sale in late 2008.
- Expense Reduction: Research and Development (R&D) expenses decreased 39% (three months) and 34% (nine months) year-over-year, driven by the Novartis asset sale, workforce reductions, and the cessation of pulmonary program research. General and Administrative (G&A) expenses decreased 20% year-over-year.
- Liquidity Position: Cash and cash equivalents decreased from $155.6 million at December 31, 2008, to $32.8 million at September 30, 2009. However, short-term investments increased to $242.9 million. Net cash used in operating activities was $90.5 million for the nine months ended September 30, 2009.
- Margin Compression: Product gross margin declined from 44% to 24% (three months) and 38% to 14% (nine months) due to a shift in product mix, decreased manufacturing volumes leading to unabsorbed overhead, and a one-time payment to a former consulting firm.
Guidance, Outlook, and Material Events
- AstraZeneca Agreement (Subsequent Event): On September 20, 2009, Nektar entered into a License Agreement with AstraZeneca AB for the worldwide development and commercialization of NKTR-118 (for opioid-induced constipation) and NKTR-119. The agreement includes a $125.0 million upfront payment received in October 2009, plus potential development milestones of up to $235.0 million and sales milestones of up to $375.0 million for NKTR-118.
- Potential License Extension: A collaboration partner has a one-time license extension option exercisable in December 2009. If exercised, Nektar expects to receive a $31.0 million cash payment.
- Facility Relocation: On September 30, 2009, Nektar entered into a sublease with Pfizer for a new 102,283 square foot facility in Mission Bay, San Francisco. Lease payments are non-cancelable and begin in 2014, with total future minimum payments of $21.3 million through 2020.
- Outlook: Management expects revenue to decrease in 2009 due to the loss of Novartis-related revenue streams, offset partially by the new AstraZeneca deal. The company anticipates continuing to incur substantial losses and negative cash flow from operations as it advances its pipeline.
- Risks: Key risks include the inherent uncertainty of drug development, reliance on partners for commercialization, potential inability to raise additional capital, and the impact of the global credit crisis on partner funding and investment liquidity.
Investor Verification Checklist
- AstraZeneca Deal Terms: Verify the amortization schedule for the $125 million upfront payment and the specific clinical milestones required to trigger the $235 million in development payments.
- Liquidity Runway: Assess whether the remaining $275.7 million in cash and investments is sufficient to fund operations and debt service obligations until the next potential revenue event (e.g., the $31 million license extension in December 2009).
- Debt Obligations: Review the terms of the $215 million in convertible subordinated notes due in September 2012 and the company's ability to refinance or repay them given current cash burn rates.
- Manufacturing Capacity: Confirm the status of the transition to the new Mission Bay facility and any potential disruptions to current manufacturing or clinical supply chains.
- Novartis Asset Sale Residuals: Verify the status of any remaining royalty rights or indemnification liabilities stemming from the December 2008 sale of pulmonary assets to Novartis.